AI-generated analysis. Always verify with the original filing.
Aptose Biosciences shareholders approved its acquisition by Hanmi Pharmaceutical, with the transaction expected to close by end of April 2026, while reporting a net loss of $25.5 million for 2025.
Event Type
Disclosure
Voluntary
Variant
8-K
. Regulation FD Disclosure.** On March 31, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated h
. Financial Statements and Exhibits.** (d) Exhibits | Exhibit Number | | Description | |---|---|---| | | | | | 99.1 | | Press Release dated March 31, 2026 | | 1
| Metric | Value | Basis |
|---|---|---|
| Research and development expenses | $11.3K | |
| General and administrative expenses | $13.4K | |
| Total operating expenses | $24.7K | |
| Net loss | $-25.5K | |
| Net loss per common share | $-10.41 |
Acquisition / Disposition